TIDMTILS
RNS Number : 0848O
Tiziana Life Sciences PLC
05 February 2021
APPOINTMENT OF DIRECTOR
5 February 2021
NEW YORK and LONDON - February 5, 2021 (GLOBE NEWSWIRE) -
Tiziana Life Sciences plc (NASDAQ: TLSA / LSE: TILS) ("Tiziana" or
the "Company"), a biotechnology company focused on innovative
therapeutics for oncology, inflammation, and infectious diseases,
today announces the appointment of Dr Thomas Adams, Ph.D. as an
executive director.
Dr Adams will assume the position of Head of Drug Development
with immediate effect and his executive role will be to manage and
oversee all matters relating to the Company's pre-clinical and
clinical drug development programs and associated intellectual
property.
Dr Thomas H Adams (age: 78)
Dr. Adams holds a Ph.D. in Biochemistry from the University of
California, Riverside. The Board believes that Dr. Adams' executive
leadership and the extensive healthcare expertise he has developed
makes Dr. Adams ideally qualified to serve as an additional
director of the Company.
Dr Adams, has been a director of Cardiff Oncology, Inc (NASDAQ:
CRDF) ("Cardiff") since June 2018, serving in the roles of Chief
Executive Officer from June 2018 to May 2020, as chairman of the
board from April 2009 to December 2020 and as Executive Chairman
from May through December 2020.
At Cardiff, Dr Adams led the development and repurposing of
onvansertib, a first-in-class, third-generation Polo-like Kinase 1
(PLK1) inhibitor, in combination with standard-of-care chemotherapy
and targeted therapeutics, for the potential treatment of
KRAS-mutated metastatic colorectal cancer (mCRC), metastatic
castration-resistant prostate cancer and relapsed or refractory
acute myeloid leukemia.
He is currently a Director at Hepion Pharmaceuticals, Inc.
(NASDAQ: HEPA) where he has served since 2014. Previously, Dr.
Adams served as Chairman of Clearbridge BioPhotonics, Inc., an
imaging solutions company, from 2013 to 2019, and as Director of
Synergy Pharmaceuticals, Inc. from 2009 to 2019.
He served in several leadership roles at IRIS International,
including Director, Head of Personalized Medicine and Chief
Technology Officer, from 2005 until the company's acquisition by
Danaher Corporation in 2012.
From 1998 to 2006, Dr. Adams was Chairman and Chief Executive
Officer of Leucadia Technologies, a privately held biotechnology
company which was acquired by IRIS International, Inc. in 2006.
Dr. Adams founded Genta, Inc. in 1989 and served as its Chief
Executive Officer until 1997. He also founded Gen-Probe, Inc. in
1984 and served as Chairman and Chief Executive Officer until its
acquisition by Chugai Biopharmaceuticals, Inc. in 1989.
Dr Adams stated, " I am excited to join the team at Tiziana to
focus on developing foralumab and milciclib. These new targeted
therapies promise to deliver relief to patients suffering from
cancer, inflammatory and infectious disease. My experience in
precision medicine utilizing targeted therapies with precision
diagnostics should accelerate the delivery of these important
therapeutics."
Gabriele Cerrone, Chairman of Tiziana, said "We are delighted to
welcome Dr Adams to the Board and consider that his proven track
record in the field of cancer could add significant value to the
development of the Company's Milciclib and Foralumab oncology
programs."
This announcement contains inside information.
Pursuant to Listing Rule 9.6.13, in connection with Dr Adams'
appointment, Dr Adams was Executive Chairman of Synergy
Pharmaceuticals Inc. until October 2018. In December 2018 Synergy
Pharmaceuticals Inc. (then listed on NASDAQ), filed for Chapter 11
bankruptcy in the USA. The company currently remains in the
administration process. There are no other disclosures to make
pursuant to Listing Rule 9.6.13, in respect of Dr Adams'
appointment.
About Tiziana Life Sciences
Tiziana Life Sciences plc is a UK biotechnology company that
focuses on the discovery and development of novel molecules to
treat human disease in oncology and immunology. In addition to
Milciclib, the Company is also developing Foralumab for liver
diseases. Foralumab is the only fully human anti-CD3 monoclonal
antibody in clinical development in the world. This Phase 2
compound has potential application in a wide range of autoimmune
and inflammatory diseases, such as nonalcoholic steatohepatitis
(NASH), ulcerative colitis, multiple sclerosis, type-1 diabetes
(T1D), Crohn's disease, psoriasis and rheumatoid arthritis, where
modulation of a T-cell response is desirable. The company is
accelerating development of anti-Interleukin 6 receptor (IL6R) mAb,
a fully human monoclonal antibody for treatment of IL6-induced
inflammation, especially for treatment of COVID-19 patients.
For further enquiries:
United Kingdom Investors:
Tiziana Life Sciences plc
Gabriele Cerrone, Chairman and founder +44 (0)20 7495 2379
U.S. Investor Contact:
RedChip Companies, Inc.
Dave Gentry
407-491-4498
dave@redchip.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOASSLEELEFSESE
(END) Dow Jones Newswires
February 05, 2021 02:00 ET (07:00 GMT)
Tiziana Life Sciences (LSE:TILS)
Historical Stock Chart
From Apr 2024 to May 2024
Tiziana Life Sciences (LSE:TILS)
Historical Stock Chart
From May 2023 to May 2024